Novartis’ Afinitor Ambitions Set Back By Phase III Liver Cancer Failure
This article was originally published in The Pink Sheet Daily
Announcing the failure of the Phase III EVOLVE-1 study of Afinitor in liver cancer, Novartis says that current approvals won’t be affected and that it plans to press on with Phase III studies in other indications.
You may also be interested in...
Its cancer pipeline planned with combinations in mind, the world’s second largest oncology company is positioned to ride the crest of the new wave in cancer drug development. Novartis is also paving new ground with quality of life research, an area of growing importance for oncology.
The blockbuster leukemia drug will likely face generic competition in 2015, putting pressure on Novartis to bring new cancer drugs to market to make up for the lost sales. The company has several promising mid- to late-stage candidates in the pipeline, but developing another blockbuster the likes of Gleevec won’t be easy.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.